Investigation of a multi-biomarker disease activity score in rheumatoid arthritis by comparison with magnetic resonance imaging, computed tomography, ultrasonography, and radiography parameters of inflammation and damage

S. Krabbe; R. Bolce; C. Brahe Pedersen; U. M. Døhn; B. Ejbjerg; M. Hetland; E. Sasso; D. Chernoff; M. S. Hansen; L. Knudsen; A. Hansen; O. R. Madsen; M. Hasselquist; J. Møller; M. Østergaard

doi:10.1080/03009742.2016.1211315

Investigation of a multi-biomarker disease activity score in rheumatoid arthritis by comparison with magnetic resonance imaging, computed tomography, ultrasonography, and radiography parameters of inflammation and damage

S. Krabbe^*, R. Bolce, C. Brahe Pedersen, U. M. Døhn, B. Ejbjerg, M. Hetland, E. Sasso, D. Chernoff, M. S. Hansen, L. Knudsen, A. Hansen, O. R. Madsen, M. Hasselquist, J. Møller, M. Østergaard

^*Corresponding author af dette arbejde

Institut for Klinisk Medicin

10 Citationer (Scopus)

Abstract

Objectives: To investigate the multi-biomarker disease activity (MBDA) score by comparison with imaging findings in an investigator-initiated rheumatoid arthritis (RA) trial (HURRAH trial, NCT00696059). Method: Fifty-two patients with established RA initiated adalimumab treatment and had magnetic resonance imaging (MRI), ultrasonography (US), computed tomography (CT), and radiography performed at weeks 0, 26, and 52. Serum samples were analysed using MBDA score assays and associations between clinical measures, MBDA score, and imaging findings were investigated. Results: The MBDA score correlated significantly with MRI synovitis (rho = 0.65, p < 0.001), MRI bone marrow oedema (rho = 0.36, p = 0.044), and US power Doppler (PD) score at week 26 (rho = 0.35, p = 0.039) but not at week 0 or week 52. In the 15 patients who had achieved a Disease Activity Score based on C-reactive protein (DAS28-CRP) < 2.6 at week 26, MRI and/or US detected subclinical inflammation and 13 (87%) had a moderate/high MBDA score. For the cohort with available data, none of the four patients in MBDA remission (score ≤ 25) at week 26 had progression of imaging damage from baseline to week 52 whereas progression was observed in three out of nine (33%) and seven out of 21 (33%) patients with moderate (30–44) and high (> 44) MBDA scores, respectively. Conclusions: In this cohort, the MBDA score correlated poorly with MRI/US inflammation. However, the MBDA score and MRI/US were generally concordant in showing signs of inflammation in most patients in clinical remission during anti-tumour necrosis factor (anti-TNF) therapy. MBDA scores were elevated in all patients with structural damage progression.

Originalsprog	Engelsk
Tidsskrift	Scandinavian Journal of Rheumatology
Vol/bind	46
Udgave nummer	5
Sider (fra-til)	353-358
Antal sider	6
ISSN	0300-9742
DOI	https://doi.org/10.1080/03009742.2016.1211315
Status	Udgivet - 3 sep. 2017

Adgang til dokumentet

10.1080/03009742.2016.1211315

Fingeraftryk

Dyk ned i forskningsemnerne om 'Investigation of a multi-biomarker disease activity score in rheumatoid arthritis by comparison with magnetic resonance imaging, computed tomography, ultrasonography, and radiography parameters of inflammation and damage'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Krabbe, S., Bolce, R., Brahe Pedersen, C., Døhn, U. M., Ejbjerg, B., Hetland, M., Sasso, E., Chernoff, D., Hansen, M. S., Knudsen, L., Hansen, A., Madsen, O. R., Hasselquist, M., Møller, J., & Østergaard, M. (2017). Investigation of a multi-biomarker disease activity score in rheumatoid arthritis by comparison with magnetic resonance imaging, computed tomography, ultrasonography, and radiography parameters of inflammation and damage. Scandinavian Journal of Rheumatology, 46(5), 353-358. https://doi.org/10.1080/03009742.2016.1211315

Investigation of a multi-biomarker disease activity score in rheumatoid arthritis by comparison with magnetic resonance imaging, computed tomography, ultrasonography, and radiography parameters of inflammation and damage. / Krabbe, S.; Bolce, R.; Brahe Pedersen, C. et al.
I: Scandinavian Journal of Rheumatology, Bind 46, Nr. 5, 03.09.2017, s. 353-358.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Krabbe, S, Bolce, R, Brahe Pedersen, C, Døhn, UM, Ejbjerg, B, Hetland, M, Sasso, E, Chernoff, D, Hansen, MS, Knudsen, L, Hansen, A , Madsen, OR, Hasselquist, M, Møller, J & Østergaard, M 2017, 'Investigation of a multi-biomarker disease activity score in rheumatoid arthritis by comparison with magnetic resonance imaging, computed tomography, ultrasonography, and radiography parameters of inflammation and damage', Scandinavian Journal of Rheumatology, bind 46, nr. 5, s. 353-358. https://doi.org/10.1080/03009742.2016.1211315

Krabbe S, Bolce R, Brahe Pedersen C, Døhn UM, Ejbjerg B, Hetland M et al. Investigation of a multi-biomarker disease activity score in rheumatoid arthritis by comparison with magnetic resonance imaging, computed tomography, ultrasonography, and radiography parameters of inflammation and damage. Scandinavian Journal of Rheumatology. 2017 sep. 3;46(5):353-358. doi: 10.1080/03009742.2016.1211315

@article{053ead48f5c84d9081cd5db64a366fec,

title = "Investigation of a multi-biomarker disease activity score in rheumatoid arthritis by comparison with magnetic resonance imaging, computed tomography, ultrasonography, and radiography parameters of inflammation and damage",

abstract = "Objectives: To investigate the multi-biomarker disease activity (MBDA) score by comparison with imaging findings in an investigator-initiated rheumatoid arthritis (RA) trial (HURRAH trial, NCT00696059). Method: Fifty-two patients with established RA initiated adalimumab treatment and had magnetic resonance imaging (MRI), ultrasonography (US), computed tomography (CT), and radiography performed at weeks 0, 26, and 52. Serum samples were analysed using MBDA score assays and associations between clinical measures, MBDA score, and imaging findings were investigated. Results: The MBDA score correlated significantly with MRI synovitis (rho = 0.65, p < 0.001), MRI bone marrow oedema (rho = 0.36, p = 0.044), and US power Doppler (PD) score at week 26 (rho = 0.35, p = 0.039) but not at week 0 or week 52. In the 15 patients who had achieved a Disease Activity Score based on C-reactive protein (DAS28-CRP) < 2.6 at week 26, MRI and/or US detected subclinical inflammation and 13 (87%) had a moderate/high MBDA score. For the cohort with available data, none of the four patients in MBDA remission (score ≤ 25) at week 26 had progression of imaging damage from baseline to week 52 whereas progression was observed in three out of nine (33%) and seven out of 21 (33%) patients with moderate (30–44) and high (> 44) MBDA scores, respectively. Conclusions: In this cohort, the MBDA score correlated poorly with MRI/US inflammation. However, the MBDA score and MRI/US were generally concordant in showing signs of inflammation in most patients in clinical remission during anti-tumour necrosis factor (anti-TNF) therapy. MBDA scores were elevated in all patients with structural damage progression.",

author = "S. Krabbe and R. Bolce and {Brahe Pedersen}, C. and D{\o}hn, {U. M.} and B. Ejbjerg and M. Hetland and E. Sasso and D. Chernoff and Hansen, {M. S.} and L. Knudsen and A. Hansen and Madsen, {O. R.} and M. Hasselquist and J. M{\o}ller and M. {\O}stergaard",

year = "2017",

month = sep,

day = "3",

doi = "10.1080/03009742.2016.1211315",

language = "English",

volume = "46",

pages = "353--358",

journal = "Scandinavian Journal of Rheumatology",

issn = "0300-9742",

publisher = "Taylor & Francis",

number = "5",

}

TY - JOUR

T1 - Investigation of a multi-biomarker disease activity score in rheumatoid arthritis by comparison with magnetic resonance imaging, computed tomography, ultrasonography, and radiography parameters of inflammation and damage

AU - Krabbe, S.

AU - Bolce, R.

AU - Brahe Pedersen, C.

AU - Døhn, U. M.

AU - Ejbjerg, B.

AU - Hetland, M.

AU - Sasso, E.

AU - Chernoff, D.

AU - Hansen, M. S.

AU - Knudsen, L.

AU - Hansen, A.

AU - Madsen, O. R.

AU - Hasselquist, M.

AU - Møller, J.

AU - Østergaard, M.

PY - 2017/9/3

Y1 - 2017/9/3

N2 - Objectives: To investigate the multi-biomarker disease activity (MBDA) score by comparison with imaging findings in an investigator-initiated rheumatoid arthritis (RA) trial (HURRAH trial, NCT00696059). Method: Fifty-two patients with established RA initiated adalimumab treatment and had magnetic resonance imaging (MRI), ultrasonography (US), computed tomography (CT), and radiography performed at weeks 0, 26, and 52. Serum samples were analysed using MBDA score assays and associations between clinical measures, MBDA score, and imaging findings were investigated. Results: The MBDA score correlated significantly with MRI synovitis (rho = 0.65, p < 0.001), MRI bone marrow oedema (rho = 0.36, p = 0.044), and US power Doppler (PD) score at week 26 (rho = 0.35, p = 0.039) but not at week 0 or week 52. In the 15 patients who had achieved a Disease Activity Score based on C-reactive protein (DAS28-CRP) < 2.6 at week 26, MRI and/or US detected subclinical inflammation and 13 (87%) had a moderate/high MBDA score. For the cohort with available data, none of the four patients in MBDA remission (score ≤ 25) at week 26 had progression of imaging damage from baseline to week 52 whereas progression was observed in three out of nine (33%) and seven out of 21 (33%) patients with moderate (30–44) and high (> 44) MBDA scores, respectively. Conclusions: In this cohort, the MBDA score correlated poorly with MRI/US inflammation. However, the MBDA score and MRI/US were generally concordant in showing signs of inflammation in most patients in clinical remission during anti-tumour necrosis factor (anti-TNF) therapy. MBDA scores were elevated in all patients with structural damage progression.

AB - Objectives: To investigate the multi-biomarker disease activity (MBDA) score by comparison with imaging findings in an investigator-initiated rheumatoid arthritis (RA) trial (HURRAH trial, NCT00696059). Method: Fifty-two patients with established RA initiated adalimumab treatment and had magnetic resonance imaging (MRI), ultrasonography (US), computed tomography (CT), and radiography performed at weeks 0, 26, and 52. Serum samples were analysed using MBDA score assays and associations between clinical measures, MBDA score, and imaging findings were investigated. Results: The MBDA score correlated significantly with MRI synovitis (rho = 0.65, p < 0.001), MRI bone marrow oedema (rho = 0.36, p = 0.044), and US power Doppler (PD) score at week 26 (rho = 0.35, p = 0.039) but not at week 0 or week 52. In the 15 patients who had achieved a Disease Activity Score based on C-reactive protein (DAS28-CRP) < 2.6 at week 26, MRI and/or US detected subclinical inflammation and 13 (87%) had a moderate/high MBDA score. For the cohort with available data, none of the four patients in MBDA remission (score ≤ 25) at week 26 had progression of imaging damage from baseline to week 52 whereas progression was observed in three out of nine (33%) and seven out of 21 (33%) patients with moderate (30–44) and high (> 44) MBDA scores, respectively. Conclusions: In this cohort, the MBDA score correlated poorly with MRI/US inflammation. However, the MBDA score and MRI/US were generally concordant in showing signs of inflammation in most patients in clinical remission during anti-tumour necrosis factor (anti-TNF) therapy. MBDA scores were elevated in all patients with structural damage progression.

U2 - 10.1080/03009742.2016.1211315

DO - 10.1080/03009742.2016.1211315

M3 - Journal article

C2 - 27682742

AN - SCOPUS:84988923053

SN - 0300-9742

VL - 46

SP - 353

EP - 358

JO - Scandinavian Journal of Rheumatology

JF - Scandinavian Journal of Rheumatology

IS - 5

ER -